Status:
COMPLETED
Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression
Lead Sponsor:
Mahidol University
Conditions:
Anti-Retroviral Agents
Efavirenz
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
According to the Thai National Guidelines for Treatment of HIV/AIDS 2014, the recommended first line ART regimen was 2 NRTIs backbone, TDF and FTC; plus 1 NNRTI, EFV, with RPV as an alternative one. M...
Detailed Description
According to the Thai National Guidelines for Treatment of HIV/AIDS 2014, the recommended first line ART (Anti-retroviral therapy) regimen was 2 NRTIs (nucleoside reverse transcriptase inhibitors) bac...
Eligibility Criteria
Inclusion
- on TDF/FTC/EFV for more than 3 months
- Blood HIV RNA viral load \<50 copies/mL
- CD4+ count \>200 cells/mm3
- eligible to sign the informed consent
Exclusion
- history of NRTI resistance
- on medication that potentially interact with study drug
- denied to participate in the study
Key Trial Info
Start Date :
October 27 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2018
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT03251690
Start Date
October 27 2016
End Date
April 30 2018
Last Update
May 7 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.